1. Home
  2. VCYT vs LQDA Comparison

VCYT vs LQDA Comparison

Compare VCYT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veracyte Inc.

VCYT

Veracyte Inc.

HOLD

Current Price

$34.88

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$41.90

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VCYT
LQDA
Founded
2006
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.1B
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
VCYT
LQDA
Price
$34.88
$41.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
10
Target Price
$46.00
$38.60
AVG Volume (30 Days)
824.1K
2.3M
Earning Date
02-25-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.38
N/A
Revenue
$495,141,000.00
$69,216,000.00
Revenue This Year
$16.72
$993.31
Revenue Next Year
$11.31
$219.14
P/E Ratio
$94.90
N/A
Revenue Growth
16.41
343.41
52 Week Low
$22.61
$11.26
52 Week High
$50.71
$46.67

Technical Indicators

Market Signals
Indicator
VCYT
LQDA
Relative Strength Index (RSI) 27.09 55.61
Support Level $40.29 $41.09
Resistance Level $38.98 $46.67
Average True Range (ATR) 1.84 2.69
MACD -0.64 0.08
Stochastic Oscillator 0.14 50.82

Price Performance

Historical Comparison
VCYT
LQDA

About VCYT Veracyte Inc.

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: